scholarly journals Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Womenʼs Health Initiative Study

2017 ◽  
Vol 24 (3) ◽  
pp. 252-261 ◽  
Author(s):  
Carolyn J. Crandall ◽  
JoAnn E. Manson ◽  
Chancellor Hohensee ◽  
Steve Horvath ◽  
Jean Wactawski-Wende ◽  
...  
Keyword(s):  
Genetic Variation ◽  
Hot Flashes ◽  
Tachykinin Receptor ◽  
Health Initiative ◽  
Night Sweats

Hormone Therapy for the Management of Menopausal Symptoms

2010 ◽  
Vol 23 (6) ◽  
pp. 540-547 ◽  
Author(s):  
C. Brock Woodis
Keyword(s):  
Hormone Therapy ◽  
Dosage Form ◽  
Hot Flashes ◽  
Menopausal Symptoms ◽  
Vasomotor Symptoms ◽  
Controlled Trials ◽  
Patient Evaluation ◽  
Health Initiative ◽  
Randomized Controlled ◽  
Night Sweats

Nearly 50 million women each year are projected to reach menopause by 2030. Many of these women will experience vasomotor symptoms such as night sweats and hot flashes as they enter the menopausal transition. Up until the release of the findings of the Women’s Health Initiative (WHI) studies, women were frequently prescribed hormone therapy (HT) to alleviate bothersome and sometimes debilitating menopausal symptoms as well as to prevent osteoporosis and coronary heart disease (CHD). Although the WHI studies were the first large, randomized, controlled trials that contradicted what was historically believed about the benefits of HT in postmenopausal women, important limitations including baseline demographics of WHI participants and investigation of only one HT strength/dosage form exist. HT may be a reasonable pharmacotherapy option for the management of menopausal symptoms following complete patient evaluation by experienced clinicians. Updated recommendations addressing management of menopausal symptoms, a new HT product containing the spironolactone-analogue drospirenone (DRSP), and discontinuation methods of HT are also discussed in this review.

Treatment of Menopause-Related Mood Disturbances

CNS Spectrums ◽  
2005 ◽  
Vol 10 (6) ◽  
pp. 489-497 ◽  
Author(s):  
Claudio N. Soares ◽  
Jennifer Prouty ◽  
Leslie Born ◽  
Meir Steiner
Keyword(s):  
Hormone Therapy ◽  
Hot Flashes ◽  
Menopausal Transition ◽  
Health Initiative ◽  
Estrogen Receptor Modulators ◽  
Increased Risk ◽  
Hormonal Fluctuations ◽  
Night Sweats ◽  
Receptor Modulators

AbstractMore than 1.7 million American women are expected to reach menopause each year. Recent Canadian statistics show that a 50-year-old woman can now expect to live until her mid-80s, which implies living at least one-third of her life after menopause. The menopausal transition is typically marked by intense hormonal fluctuations, accompanied by vasomotor symptoms (eg, hot flashes, night sweats), sleeps disturbance, and changes in sexual function, as well as increased risk for osteoporosis, cardiovascular disease, and cognitive decline. More importantly, recent studies have demonstrated a significant association between menopausal transition and a higher risk for developing depression. In the post-Women's Health Initiative Study era, physicians and patients are questioning the safety and efficacy of long-term hormone therapy use. This article reviews the current literature on the benefits and risks of using hormone therapy for the treatment of menopause-related mood disturbances and alternate strategies currently available for the management of menopause-related problems, including antidepressants, complementary and alternative medicine, and selective estrogen receptor modulators.

scholarly journals Genetic Variation and Hot Flashes: A Systematic Review

2020 ◽  
Vol 105 (12) ◽  
pp. e4907-e4957
Author(s):  
Carolyn J Crandall ◽  
Allison L Diamant ◽  
Margaret Maglione ◽  
Rebecca C Thurston ◽  
Janet Sinsheimer
Keyword(s):  
Genetic Variation ◽  
Genome Wide Association Study ◽  
Evidence Synthesis ◽  
Meta Analysis ◽  
Statistical Significance ◽  
Hot Flashes ◽  
Single Nucleotide Variants ◽  
A Genome ◽  
Night Sweats ◽  
Cytochrome P450 Family

Abstract Context Approximately 70% of women report experiencing vasomotor symptoms (VMS, hot flashes and/or night sweats). The etiology of VMS is not clearly understood but may include genetic factors. Evidence Acquisition We searched PubMed and Embase in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidance. We included studies on associations between genetic variation and VMS. We excluded studies focused on medication interventions or prevention or treatment of breast cancer. Evidence Synthesis Of 202 unique citations, 18 citations met the inclusion criteria. Study sample sizes ranged from 51 to 17 695. Eleven of the 18 studies had fewer than 500 participants; 2 studies had 1000 or more. Overall, statistically significant associations with VMS were found for variants in 14 of the 26 genes assessed in candidate gene studies. The cytochrome P450 family 1 subfamily A member 1 (CYP1B1) gene was the focus of the largest number (n = 7) of studies, but strength and statistical significance of associations of CYP1B1 variants with VMS were inconsistent. A genome-wide association study reported statistically significant associations between 14 single-nucleotide variants in the tachykinin receptor 3 gene and VMS. Heterogeneity across trials regarding VMS measurement methods and effect measures precluded quantitative meta-analysis; there were few studies of each specific genetic variant. Conclusions Genetic variants are associated with VMS. The associations are not limited to variations in sex-steroid metabolism genes. However, studies were few and future studies are needed to confirm and extend these findings.

Abstract P724: Perimenopausal Women With Migraine Present With Stroke at a Younger Age and With Less Comorbid Diabetes

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Morgan Figurelle ◽  
Dawn M Meyer ◽  
Emily Perrinez ◽  
Karen Rapp ◽  
Rebecca Wells ◽  
...  
Keyword(s):  
Native American ◽  
Ischemic Stroke ◽  
Menopausal Status ◽  
Hot Flashes ◽  
Future Research ◽  
Significant Difference ◽  
Perimenopausal Women ◽  
Chi Squared ◽  
Night Sweats ◽  
Comprehensive Stroke Center

Introduction: Migraine is an independent risk factor for ischemic stroke. Frequency and severity increases in the perimenopausal period accompanied by marked vasomotor symptoms (VMS) such as hot flashes, flushing and night sweats. There is emerging evidence that VMS increases the risk of vascular disease including stroke. The purpose of this study was describe the demographics and co-morbidities of perimenopausal females with and without migraine that experience acute ischemic stroke (AIS). Methods: In this IRB approved study, electronic health record (EHR) data was obtained from a large, academic, comprehensive stroke center from 1/1/2015 to 1/1/2020. Inclusion criteria included female sex, age 42-65 years, and hospital diagnosis code of AIS. Hemorrhagic stroke, TIA, vasculopathy, and endocarditis associated strokes were excluded. Perimenopause was defined as age ≥42 and ≤65 years. Hormonal and menopausal status was not available in the EHR. We compared the baseline demographics and co-morbidities by ICD10 codes of subjects with and without migraine. Chi squared was used to compare categorical data and t test for continuous. Spearman rho was used to assess correlations. Results: We identified 660 subjects who met study criteria (n=83 with migraine; n=577 without migraine). Migraine positive subjects were significantly younger (mean age 58 vs 66 years, p=0.03) at time of AIS. Migraine positive subjects identified significantly more often as White (47%) compared to Black (10%), Asian (7%), Pacific Islander (1%), Native American/Alaskan (1%), Other/Mixed Race (31%), and unknown (3%), p=0.001. There was no significant difference in Hispanic ethnicity (p=0.87), hypertension (p=0.66), hyperlipidemia (p=0.12), or atrial fibrillation (p=0.84). Comorbid diabetes was significantly higher in the non-migraine group (94% vs 6%, p<0.001). Conclusion: Perimenopausal women with concomitant history of migraine present with AIS at younger ages and with lower rates of diabetes than those without a migraine history. Future research must be done to assess the correlation of menopausal symptom severity, hormone levels at time of AIS, and stroke characteristics to further understand the role of menopause in stroke risk.

Using Traditional Acupuncture for Breast Cancer-Related Hot Flashes and Night Sweats

2010 ◽  
Vol 16 (10) ◽  
pp. 1047-1057 ◽  
Author(s):  
Beverley A. de Valois ◽  
Teresa E. Young ◽  
Nicola Robinson ◽  
Christine McCourt ◽  
Elizabeth J. Maher
Keyword(s):  
Breast Cancer ◽  
Hot Flashes ◽  
Night Sweats

NADA Ear Acupuncture for Breast Cancer Treatment–Related Hot Flashes and Night Sweats: An Observational Study

2012 ◽  
Vol 24 (4) ◽  
pp. 256-268 ◽  
Author(s):  
Beverley de Valois ◽  
Teresa E. Young ◽  
Nicola Robinson ◽  
Christine McCourt ◽  
Elizabeth Jane Maher
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Cancer Treatment ◽  
Hot Flashes ◽  
Breast Cancer Treatment ◽  
Ear Acupuncture ◽  
Night Sweats

Determinants of hot flashes and night sweats

2006 ◽  
Vol 33 (1) ◽  
pp. 4-16 ◽  
Author(s):  
Lynnette Leidy Sievert ◽  
Carla Makhlouf Obermeyer ◽  
Kim Price
Keyword(s):  
Hot Flashes ◽  
Night Sweats

scholarly journals Comparative Efficacy of Zolpidem and Nigella Sativa in Treatment of Sleep Disorder and Vasomotor Symptoms in Menopausal Women of Women’s General Hospital

2020 ◽  
Author(s):  
Mojgan Asadi ◽  
Fatemeh Molavi ◽  
Mostafa Qorbani ◽  
Fatemeh Davari Tanha
Keyword(s):  
Sleep Quality ◽  
Postmenopausal Women ◽  
Nigella Sativa ◽  
Controlled Trial ◽  
Hot Flashes ◽  
Vasomotor Symptoms ◽  
Double Blind ◽  
Menopausal Women ◽  
Night Sweats ◽  
Group B

Objective: To evaluate the efficacy of Zolpidem and Nigella sativa compared to placebo in treatment of sleep disturbance in healthy postmenopausal women. Menopause is a period that diagnosed after 12 months of amenorrhea and is characterized by a group of symptoms that include irregular menses; vasomotor and urogenital symptoms. The effects of non-hormonal therapies are being widely researched on menopause symptoms. There has been no study to compare Zolpidem and Nigella sativa versus placebo. Materials and methods: In this double-blind, placebo controlled trial, we compared the effect of Zolpidem with Nigella sativa and placebo in reducing sleep quality in 60 menopausal women. The prior and the later results were compared. We divided the patients into three groups after history taking and physical examination and filling the Pittsburgh questionnaire. Each group received their medication as the following order: Group A: Zolpidem, Group B: Nigella sativa, Group C: placebo. The first group received Zolpidem with the dose of 5 mg for 8 weeks. The second group received Nigella sativa with the dose of 600 mg for 8 weeks. The third group received placebo for 8 weeks. After two months, the Pittsburg questionnaire was filled again. Results: In the nigella sativa group, we had not significant improvement in sleep quality (p =0.07), hot flashes (p =0.15), palpitation (p =0.56) and night sweets (p =0.08).  In zolpidem group, we have seen lack of improvement of hot flashes (p =0.73), and palpitation (p =0.36), which are nonsignificant statistically according to p values, but in zolpidem group, we had significant improvement in sleep quality (p =0.01), and night sweats (p =0.049). Conclusion: It seems that zolpidem has some effect on improving the quality of sleep in postmenopausal women. zolpidem also is good for night sweats. Nigella sativa was not effective in vasomotor symptoms and sleep quality.

Sign in / Sign up

Export Citation Format

Share Document